The coronavirus stopped a bull market dead in in its tracks this year. From the market peak on February 20, the S&P 500—proxied by the SPDR S&P 500 Trust (NYSE Arca: SPY)—has lost 14.7 percent to date. For the one-year period preceding the break, SPY was up 23 percent.
All sectors of the market were affected by the coronavirus scare, but not equally. Owners of health care stocks—at least those included in the S&P 500—would have hardly noticed the market upset. The Health Care Select Sector SPDR (NYSE Arca: XLV) hastickeddownjust 3 percent since February 20, after a 1-year gain of 14 percent. A 3 percent slump over 53 trading days is well within the ETF’s normal volatility range.
The same can be said for the Technology Select Sector SPDR (NYSE Arca: XLK). Big tech is off less than 10 percent in the virus’ wake. For an ETF with a standard deviation well in excess of the S&P 500’s, a much bigger drawdown could have reasonably been expected.
That health care stocks are relatively buoyant isn’t really a surprise. The sector tends to fare well in the early stages of a bear market. Perhaps especially in this downturn, since its genesis is a medical crisis. And most particularly because many XLV companies are researching COVID-19 vaccines and treatments.
At the top of XLV’s 61-stock portfolio—representing more than 10 percent of the ETF’s capitalization—is Johnson & Johnson (NYSE: JNJ). The company, through its Janssen Pharmaceutical Companies partnership with the Biomedical Advanced Research and Development Authority (BARDA), is working on a vaccine with the objective of supplying more than a billion doses by early 2021. JNJ’s Janssen subsidiary identified a potential vaccine candidate back in January. Taking note of this, investors have pushed up JNJ’s stock 1.4 percent since the February 20 break.
Pfizer Inc. (NYSE: PFE)accounts for 5.6 percent of XLV’s market weight and is preparing, in collaboration with the German firm BioNTech SE (Nasdaq: BNTX), its own vaccine. With its mRNA inoculation already in clinical trials, PFE’s stock has stoutly rebounded since the February break and is now ahead 7.4 percent.
Another 16 percent of XLV’s market value is given over to companies engaged in coronavirus therapies, most notably Amgen Inc. (Nasdaq: AMGN), Eli Lilly & Co. (NYSE: LLY) and AbbVie Inc. (NYSE: ABBV). Amgen, in partnership with Adaptive Biotechnologies (Nasdaq: ADPT), is aiming to develop human neutralizing antibodies to treat COVID-19 infections. Lilly is in trials assessing the efficacy of Baricitinib while AbbVie’s focused on testing the antiviral capacity of Kaletra/Aluvia.
Nine XLV constituents, making up a third of the ETF’s capitalization, are involved in some way with the control or treatment of the coronavirus. That said, it’s likely XLV’s price action will be greatly influenced by these companies’ stocks for some time to come. XLV is now trading at the $100 level. Technically, the ETF’s longer-term trend points to a $156 objective which, if attained, would certainly be a bright spot on an otherwise dim investment horizon.
There’s a cautionary note to such a sanguine prognostication. The vaccine derby may be ultimately decided in favor of one, or none, of the XLV incumbents. The “loser” risks some deflation in its stock price when a “winner” is declared.
Still, history favors the health care sector now, at both the secular and business cycle levels. Even if 50- percent appreciation doesn’t materialize, our aging demographics and the industry’s traditional role as a recession investment militate for its inclusion, and perhaps an overweight, in asset allocations.
Brad Zigler is WealthManagement's Alternative Investments Editor. Previously, he was the head of Marketing, Research and Education for the Pacific Exchange's (now NYSE Arca) option market and the iShares complex of exchange traded funds.
Take a look at our comprehensive guide to the best and most popular information ebooks and products available today on Detoxing, Colon Cleansing, Weight Loss and Dating and Romance. They are all in one spot, easy to find and compere to make a quick selection for the product that best fits your needs or wants.
So browse through a category and make your preferred selection and come back here to read more choice articles and get a few more helpful tips on ways to help your enhancement.
As an Amazon Associate I earn from qualifying purchases. “saubiosaubiosuccess.com is a participant in third party affiliate and advertising programs; The Amazon Services LLC Associates Program, Awin network, and other affiliate advertising programs are designed to provide a means for sites to earn advertising fees and commissions by advertising and linking to products on other sites and on Amazon.com. Amazon and the Amazon logo are trademarks of Amazon.com, Inc, or its affiliates.”
We use anonymous cookies and various 3rd-party services to optimise and to offer you a better, more personalised, browsing experience with advanced accessibility enhancements.
Dismiss
Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes.The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
